Ovarian Cancer Trial, Recruiting NCT03958240 Sponsor: Institut Claudius Regaud Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT03958240
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a locally advanced or metastatic solid tumour (such as head and neck cancer, ovarian cancer, cervical cancer, glioblastoma, non-small cell lung cancer, anal cancer, or other solid tumour types), or people who have been diagnosed with high-grade pre-cancerous changes of the cervix (called CIN II or CIN III)
  • People aged 18 years or older at the time of joining the study
  • People who are currently being treated or monitored under standard medical care or as part of another clinical trial
  • People whose general health and ability to carry out daily activities falls within an acceptable range, as assessed by their doctor using a standard scale (confirm with trial site)
  • People who are willing and able to give informed consent before any study-related procedures take place, and who are able to follow the study requirements
  • People who are covered by a social health insurance scheme in France
  • People who are already participating in other clinical trials may still be considered

Who may not be able to join:

  • People who have a known history of Hepatitis B, Hepatitis C, HIV, or Hanta virus
  • People for whom taking blood samples would be medically unsuitable, including those with a haemoglobin level below 8g/dl (a measure of low red blood cell levels)
  • People who are pregnant or currently breastfeeding
  • People whose psychological, family, geographic, or social circumstances may, in the investigator's judgement, prevent them from giving informed consent or following the study procedures
  • People who are under legal guardianship or whose freedom is restricted by an administrative or legal order

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +33 5 31 15 53 66

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut Claudius Regaud
Registry
ClinicalTrials.gov
Start date
17 January 2020
Est. completion
1 January 2033

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Percentage of CD4 and CD8 T cells expressing PD-1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov